New surface may kill antibiotic-resistant staph bacteria with fluorescent light
Wednesday, October 20, 2010 - 04:30
in Health & Medicine
The prevalence of methicillin-resistant Staphylococcus aureus (MRSA) infections is well known, causing an estimated 19,000 deaths and $3-4 billion in healthcare costs per year in the U.S. What is less well known is that this increased infection and resistance rate has not been met with a simultaneous development of novel antimicrobial and antibiotic agents; in fact, only three classes of antibiotics have been developed since the 1950s.